Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1684-1687

  De Jesús, Víctor R ^a   Simms, David A ^a   Schiffer, Jarad ^b   Kennedy, Meredith ^a   Mei, Joanne V ^a   Hannon, W Harry ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Congenital adrenal hyperplasia; Dried blood spot; Newborn screening; Proficiency testing; Second tier testing; Tandem mass spectrometry

Indexed keywords

ANDROSTENEDIONE; HYDROCORTISONE; HYDROXYPROGESTERONE;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; MATERIALS TESTING; NEWBORN SCREENING; PILOT STUDY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ANDROSTENEDIONE; HUMANS; HYDROCORTISONE; INFANT, NEWBORN; NEONATAL SCREENING; PILOT PROJECTS; STEROIDS; TANDEM MASS SPECTROMETRY;

EID: 77956478138     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.029     Document Type: Article

References (18)

1. Lacey J.M., Minutti C.Z., Magera M.J., Tauscher A.L., Casetta B., McCann M., et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004, 50:621-625.
2. Minutti C.Z., Lacey J.M., Magera M.J., Hahn S.H., McCann M., Schulze A., et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004, 89:3687-3693.
3. Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. Pediatrics 2000, 106:1511-1518.
4. al Saedi S., Dean H., Dent W., Stockl E., Cronin C. Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics 1996, 97:100-102.
5. Fingerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids 2009, 74:662-665.
6. Kosel S., Burggraf S., Fingerhut R., Dorr H.G., Roscher A.A., Olgemoller B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 2005, 51:298-304.
7. Torresani T.G.A., Scherz R., Burckhardt J.J., Harras A., Zachmann M. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17-hydroxyprogesterone to gestational age. Screening 1994, 3:77-84.
8. Allen D.B., Hoffman G.L., Fitzpatrick P., Laessig R., Maby S., Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997, 130:128-133.
9. Olgemoller B., Roscher A.A., Liebl B., Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 2003, 88:5790-5794.
10. Speiser P.W. Improving neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004, 89:3685-3686.
11. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347:3-11.
12. Janzen N., Peter M., Sander S., Steuerwald U., Terhardt M., Holtkamp U. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007, 92:2581-2589.
13. Janzen N., Sander S., Terhardt M., Peter M., Sander J. Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 861:117-122.
14. Rossi C., Calton L., Hammond G., Brown H.A., Wallace A.M., Sacchetta P., et al. Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2009, 411:222-228.
15. Schwarz E., Liu A., Randall H., Haslip C., Keune F., Murray M., et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res 2009, 66:230-235.
16. Mei J.V., Alexander J.R., Adam B.W., Hannon W.H. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001, 131:1631S-1636S.
17. De Jesus V.R., Chace D.H., Lim T.H., Mei J.V., Hannon W.H. Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry. Clin Chim Acta 2010, 411:684-689.
18. De Jesus V.R., Mei J.V., Bell C.J., Hannon W.H. Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for disease Control and Prevention. Semin Perinatol 2010, 34:125-133.